Ubtech Robotics Stock Sinks to 52-Week Low as $2,300 Rival Undercuts Premium Humanoid Plans

Ubtech shares hit one-year low after rival Chunshuitang launches companion robot at 85% discount; Unitree's profitable IPO adds pressure.

Ubtech Robotics shares tumbled to a one-year low on Friday, closing at €9.60 after a 2.86% single-day drop. The intraday nadir of €9.40 marks a fresh 52-week floor, leaving the stock 43.53% below its January high of €17.00. The weekly loss now stands at 18.64%, and the year-to-date decline has widened to roughly 34%.

The trigger: a low-cost challenger from an unexpected corner. Changzhou Chunshuitang Health Technology, a company rooted in adult products manufacturing, unveiled a companion robot priced between 15,800 and 16,800 yuan — about $2,326 at current exchange rates. That undercuts Ubtech’s new UWORLD U1 series, which starts at 119,800 yuan (around $17,634) and reaches 990,000 yuan for the top “U1 Ultra” variant, by more than 85%.

Chunshuitang is also racing to market faster. Customers can pre-order now on Tmall and JD.com, with deliveries beginning August 1 — a full month ahead of Ubtech’s scheduled September rollout for the U1 series. The rival brings 23 years of experience in adult product manufacturing and, through a subsidiary, several years of robotics know-how. The company is positioning the device as a platform for “emotional AI” services rather than mere hardware.

Ubtech’s own pre-order figures are now under scrutiny. Founder Zhou Jian had touted 13,361 reservations for the U1 series. But an investigation by media outlet Dingjiao One revealed that most of those came before prices were announced, requiring only a 3,000 yuan deposit. Full refunds have been available since July 16, leaving open the question of how many will convert into paid orders.

Competitive pressure is mounting from another flank as well. Unitree Robotics, considered a global leader in humanoid robot deliveries, secured Chinese regulatory approval for an IPO on the STAR Market worth around $619 million (4.2 billion yuan). Unlike Ubtech, which has posted consecutive losses since at least 2020, Unitree reported an adjusted net profit of 600 million yuan ($90 million) for 2025 — a 674.3% surge year over year and its first profitable period ever. Unitree’s G1 model sells for just $13,500, adding fuel to the price war.

Ubtech is responding by shifting emphasis toward industrial robotics. Senior Vice President Hou Zongfang recently outlined the company’s “Physical AI” architecture, built around modular “Mini-Brains” and distributed control systems for commercial use. Ubtech plans to reach production capacity of 20,000 units in 2026, split evenly between industrial and commercial leadership robots on one side and bionic companion models on the other. Internal data showed roughly 15,000 potential orders for the bionic models alone as of early July — a figure that matches the planned annual delivery capacity, suggesting an immediate bottleneck if demand holds.

Technical indicators reinforce the bearish tone. The stock trades nearly 19% below both its 50-day moving average (€11.82) and its 100-day moving average (€11.90). The 14-day relative strength index sits at 38.0, weak but not oversold. Annualized 30-day volatility of 85.04% underscores the speculative nature of the equity. Ubtech’s market capitalization now stands at approximately €4.78 billion.

All eyes are now on two key milestones: Chunshuitang’s first deliveries on August 1, which will test whether its aggressive pricing and earlier timing can erode Ubtech’s market share, and Ubtech’s own mass shipment of the U1 series in September, which will reveal whether the initial pre-order buzz translates into real revenue.